抗HIV治療ガイドライン（2025年3月発行）

VII治療失敗時の薬剤変更

文献

  1. Joya C, Won SH, Schofield C et al. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure. Clin Infect Dis. 69:2145-52. 2019.
  2. Dijkstra S, Hofstra LM, Mudrikova T et al. Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 89:575-82. 2022.
  3. Fleming J, Mathews WC, Rutstein RM et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 33:2005-12. 2019.
  4. Elvstam O, Malmborn K, Elen S, et al. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clin Infect Dis 2023; 76(1): 25–31.
  5. Aldredge A, Mehta CC, Lahiri CD et al. Consequences of low-level viremia among women with HIV in the United States. AIDS. 38:1829-38. 2024.
  6. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (米国DHHS, Sep 12, 2024).
    https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new
  7. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 15:1369-77.2001.
  8. Harles H, Eron J., Fiscus S., et al. Transmitted HIV Resistance among Patients with Acute and Recent HIV Infection in North Carolina: Report of 102 Cases. 12th CROI abstract #673, 2005.
  9. Wensing AM, van de Vijver DA, Angarano G. et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 192: 958-66, 2005.
  10. 国内流⾏HIV 及びその薬剤耐性株の⻑期的動向把握に関する研究班, 薬剤耐性HIV インフォメーションセンター
    https://www.hiv-resistance.jp/research03.htm.
  11. 蜂谷敦子、佐藤かおり、豊嶋崇徳ら. 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向. 日本エイズ学会誌. 21:465, 2019.
  12. 菊地正、西澤雅子、椎野禎一郎ら. 2023年の国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向.日本エイズ学会誌. 26:463, 2024.
  13. King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy- naïve patients. J Infect Dis. 190: 280-4, 2004.
  14. HIV診療における外来チーム医療マニュアル改訂第4版（厚生労働行政推進調査事業費補助金（エイズ対策政策研究事業）「HIV感染症および血友病におけるチーム医療の構築と医療水準の向上を目指した研究」班）：https://osaka-hiv.jp/pdf/team_medical_manual_v4.pdf
  15. Andreatta K, Sax PE, Wohl D, et al. Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. J Antimicrob Chemother 2025; 80(1): 281-291. doi: 10.1093/jac/dkae407.
  16. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 16: 209-18, 2002.
  17. Stanford HIV Drug Resistance Database, HIVdb version 9.8 https://hivdb.stanford.edu/
  18. R. Stryker, S. Brun, M. King, et al. Kaletra (ABT-378/ritonavir) in Antiretroviral- naïve HIV+ Patients: Follow-up Beyond Two Years and Viral Load Suppression Below 3 Copies/m. 5TH INTERNATIONAL CONGRESS ON DRUG THERAPY IN HIV INFECTION, 2000.
  19. HIV薬剤耐性検査ガイドラインver.10 （日本医療研究開発機構 エイズ対策実用化研究事業「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班）：https://www.hiv-resistance.jp/resistance04.htm
  20. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 19:253-264, 2019.
  21. Paton N, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 9:e381-e393, 2022.
  22. D2EFT Study Group. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial. Lancet HIV 2024 Jul;11(7):e436-e448. doi: 10.1016/S2352-3018(24)00089-4.
  23. Segal-Maurer S, Dejesus E, Stellbrink HJ, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 386(19): 1985-1991, 2022.
  24. Ogbuagu O, Segal-Maurer S, Ratanasuwan W, et al. Efficacy and safty of nobel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.Lancet HIV. 10:e497-e505, 2023.
  25. Margot NA, Naik V, VanderVeen L, et al. Resistance analyses in highly treatmentexperienced people with human immunodeficiency virus (HIV) treated with the novel capsid HIV inhibitor lenacapavir. J Infect Dis. 226(11):1985-1991, 2022.
  26. 株式会社北里大塚バイオメディカルアッセイ研究所 高感度HIVジェノタイプ薬剤耐性検査(コード8732)
    www.kobal.co.jp/medical/medreq.php?jken2=HIV関連検査
  27. 「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班(https://www.hiv-resistance.jp/howto02.htm)

PAGE TOP